Opinion|Videos|June 4, 2024
Intravascular and Extravascular Hemolysis MoA in PNH
Medical experts illustrate the nature of hemolysis in PNH and characteristics unique to the disease state.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Please describe the mechanisms of intravascular and extravascular hemolysis in paroxysmal nocturnal hemoglobinuria (PNH).
- What distinguishes PNH from other hematological disorders in terms of its clinical manifestations, particularly focusing on hemolysis, thrombosis, and bone marrow failure?
Advertisement
Related to this article
Claims data show regorafenib is prescribed earlier than guidelines advise for a good share of patients with advanced GIST, with dosing also varying widely.
Karen van Caulil, PhD, on how employers can improve cancer care by investing in access, prevention, and support through treatment and survivorship.
Each additional hour of nightly CPAP use was associated with 13% lower all-cause mortality risk in a French cohort of adults with sleep apnea.
AI-assisted spirometry, imaging biomarkers, and population screening strategies highlighted early detection and prevention as a throughline at the ERS Congress.
Ultimately, causality could not be established due to lack of data on disease severity and socioeconomic status, among others.
A systematic review finds people with narcolepsy and idiopathic hypersomnia often stay employed but face work impairment and limited workplace support.
Laura Fabbri, MD, discusses bridging idiopathic pulmonary fibrosis (IPF) and oncology research and putting patients at the center of trial design.
Finerenone is the first new FDA-approved treatment in more than 30 years for adults with CKD associated with type 1 diabetes.
Advertisement
Advertisement
Trending on AJMC
1
Delayed Dupilumab Raises Asthma Costs 32%: Nicola Hanania, MD
2
Which Antibiotics Raise C. Diff Risk Most? Jason Pogue, PharmD
3
Regorafenib Prescribing in Advanced GIST Deviates From Guidelines
4
A Patient-Centered Reconstruction of 340B in Oncology: Transparency, Equity, and Site-of-Care Accountability
5